These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 22569393)
1. Change in macular thickness in a case of refractory diabetic macular edema with dexamethasone intravitreal implant in comparison to intravitreal bevacizumab: a case report. Sharma A; Madhusudhan RJ; Nadahalli V; Damgude SA; Sundaramoorthy SK Indian J Ophthalmol; 2012; 60(3):234-5. PubMed ID: 22569393 [TBL] [Abstract][Full Text] [Related]
2. The Interval between Treatments of Bevacizumab and Dexamethasone Implants for Diabetic Macular Edema Increased over Time in the BEVORDEX Trial. Mehta H; Fraser-Bell S; Nguyen V; Lim LL; Gillies MC Ophthalmol Retina; 2018 Mar; 2(3):231-234. PubMed ID: 31047591 [TBL] [Abstract][Full Text] [Related]
3. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Gillies MC; Lim LL; Campain A; Quin GJ; Salem W; Li J; Goodwin S; Aroney C; McAllister IL; Fraser-Bell S Ophthalmology; 2014 Dec; 121(12):2473-81. PubMed ID: 25155371 [TBL] [Abstract][Full Text] [Related]
4. Repeated Dexamethasone Intravitreal Implant for the Treatment of Diabetic Macular Oedema Unresponsive to Anti-VEGF Therapy: Outcome and Predictive SD-OCT Features. Hatz K; Ebneter A; Tuerksever C; Pruente C; Zinkernagel M Ophthalmologica; 2018; 239(4):205-214. PubMed ID: 29402873 [TBL] [Abstract][Full Text] [Related]
5. A 12-MONTH, SINGLE-MASKED, RANDOMIZED CONTROLLED STUDY OF EYES WITH PERSISTENT DIABETIC MACULAR EDEMA AFTER MULTIPLE ANTI-VEGF INJECTIONS TO ASSESS THE EFFICACY OF THE DEXAMETHASONE-DELAYED DELIVERY SYSTEM AS AN ADJUNCT TO BEVACIZUMAB COMPARED WITH CONTINUED BEVACIZUMAB MONOTHERAPY. Maturi RK; Bleau L; Saunders J; Mubasher M; Stewart MW Retina; 2015 Aug; 35(8):1604-14. PubMed ID: 25829346 [TBL] [Abstract][Full Text] [Related]
6. Anti-VEGF versus dexamethasone implant (Ozurdex) for the management of Centre involved Diabetic Macular Edema (CiDME): a randomized study. Sharma A; Bellala K; Dongre P; Reddy P Int Ophthalmol; 2020 Jan; 40(1):67-72. PubMed ID: 31377905 [TBL] [Abstract][Full Text] [Related]
7. Aqueous humour cytokine changes during a loading phase of intravitreal ranibizumab or dexamethasone implant in diabetic macular oedema. Podkowinski D; Orlowski-Wimmer E; Zlabinger G; Pollreisz A; Mursch-Edlmayr AS; Mariacher S; Ring M; Bolz M Acta Ophthalmol; 2020 Jun; 98(4):e407-e415. PubMed ID: 31736269 [TBL] [Abstract][Full Text] [Related]
8. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A Retina; 2006; 26(9):999-1005. PubMed ID: 17151486 [TBL] [Abstract][Full Text] [Related]
9. Intravitreal triamcinolone acetonide versus combined intravitreal bevacizumab and dexamethasone in diffuse diabetic macular oedema. Sheth S; Rush R; Natarajan S; Gillies M Clin Exp Ophthalmol; 2011; 39(7):673-81. PubMed ID: 22452685 [TBL] [Abstract][Full Text] [Related]
11. Effect of combination therapy with bevacizumab and dexamethasone intravitreal implant in patients with retinal vein occlusion. Singer MA; Bell DJ; Woods P; Pollard J; Boord T; Herro A; Porbandarwalla S Retina; 2012 Jul; 32(7):1289-94. PubMed ID: 22466480 [TBL] [Abstract][Full Text] [Related]
12. Intravitreal bevacizumab (Avastin) treatment of diffuse diabetic macular edema in an Indian population. Kumar A; Sinha S Indian J Ophthalmol; 2007; 55(6):451-5. PubMed ID: 17951903 [TBL] [Abstract][Full Text] [Related]
13. Intravitreal bevacizumab and dexamethasone implant for treatment of chronic diabetic macular edema. Güler E; Totan Y; Betül Güragaç F Cutan Ocul Toxicol; 2017 Jun; 36(2):180-184. PubMed ID: 28366074 [TBL] [Abstract][Full Text] [Related]
14. Imaging retinal inflammatory biomarkers after intravitreal steroid and anti-VEGF treatment in diabetic macular oedema. Vujosevic S; Torresin T; Bini S; Convento E; Pilotto E; Parrozzani R; Midena E Acta Ophthalmol; 2017 Aug; 95(5):464-471. PubMed ID: 27775223 [TBL] [Abstract][Full Text] [Related]
15. PROSPECTIVE RANDOMIZED SUBJECT-MASKED STUDY OF INTRAVITREAL BEVACIZUMAB MONOTHERAPY VERSUS DEXAMETHASONE IMPLANT MONOTHERAPY IN THE TREATMENT OF PERSISTENT DIABETIC MACULAR EDEMA. Shah SU; Harless A; Bleau L; Maturi RK Retina; 2016 Oct; 36(10):1986-96. PubMed ID: 27124881 [TBL] [Abstract][Full Text] [Related]
16. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. Callanan DG; Loewenstein A; Patel SS; Massin P; Corcóstegui B; Li XY; Jiao J; Hashad Y; Whitcup SM Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):463-473. PubMed ID: 27632215 [TBL] [Abstract][Full Text] [Related]
17. Evolution of vitreomacular traction following the use of the dexamethasone intravitreal implant (Ozurdex) in the treatment of macular edema secondary to central retinal vein occlusion. Bakri SJ; Omar AF J Ocul Pharmacol Ther; 2012 Oct; 28(5):547-9. PubMed ID: 22537269 [TBL] [Abstract][Full Text] [Related]
18. Dexamethasone intravitreous implant versus bevacizumab for central retinal vein occlusion-related macular oedema: a prospective randomized comparison. Gado AS; Macky TA Clin Exp Ophthalmol; 2014; 42(7):650-5. PubMed ID: 24612095 [TBL] [Abstract][Full Text] [Related]
19. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema. Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710 [TBL] [Abstract][Full Text] [Related]
20. Treatment of anti-vascular endothelial growth factor-resistant diabetic macular edema with dexamethasone intravitreal implant. Lazic R; Lukic M; Boras I; Draca N; Vlasic M; Gabric N; Tomic Z Retina; 2014 Apr; 34(4):719-24. PubMed ID: 23975006 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]